Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Request metadata listed Altimmune, Inc., but the filing text identifies PharmAthene, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2008
Event: Completion of the acquisition of substantially all assets related to Avecia Biologics Limited's biodefense vaccines business.
Key Financial Metrics and Transaction Terms
Acquisition Consideration:
- Initial Consideration: $10 million cash paid at closing (subject to working capital adjustment).
- Deferred Consideration: $7 million secured by a letter of credit. Payable upon the earlier of: (a) completion of a financing transaction with gross proceeds of at least $15 million, or (b) 18 months post-consummation.
- Milestone Consideration: Potential future payments totaling up to $23 million plus royalties, contingent on specific government contracts and sales milestones.
Acquired Assets: Products, patents, trademarks, domain names, license agreements, contracts, goodwill, and intangibles related to anthrax and plague vaccines.
Personnel Acquired: 51 employees in Billingham, UK, and 6 employees in Milford, Massachusetts.
Historical Funding of Acquired Programs: Approximately $220 million in total government funding previously obtained by Avecia for these programs ($135 million for anthrax, $92 million for plague).
Material Changes and Amendments
The original Purchase Agreement was amended on April 2, 2008, immediately prior to closing due to a US Department of Defense decision not to fund the plague vaccine candidate beyond current commitments. Key changes include:
- Deferred Consideration Reduction: Reduced from $10 million to $7 million.
- Payment Timeline Extension: Extended from 12 months to 18 months post-consummation.
- New Milestone: Added a $3 million milestone payment upon entering a multi-year funded contract for the plague vaccine (rYP) with a total committed value exceeding $30 million.
- Restrictive Covenants: Amended to allow Avecia to enter into manufacturing arrangements for other plague vaccines under specific conditions.
Outlook, Risks, and Management Commentary
Product Pipeline:
- rPA Anthrax Vaccine: Second-generation vaccine; completed two Phase II trials in over 700 adults. Safe and well-tolerated. $44 million in remaining government funding supports development through end of 2009.
- rYP Plague Vaccine: Recombinant dual antigen vaccine; completed three Phase I studies. Entering Phase II trials in Q2 2008. Approximately $20 million in remaining funding supports development into H1 2009.
- Third Generation rPA: In development for improved stability (3 years at 35°C) and reduced dosing. Supported by NIH grants since 2005.
Risks and Contingencies:
- Financing Risk: Deferred consideration payment is contingent on PharmAthene securing $15 million in gross proceeds from a financing transaction.
- Government Funding Dependency: Future development relies heavily on US and UK government contracts and grants.
- Forward-Looking Statements: The filing contains forward-looking statements regarding financial results and regulatory approvals which are subject to risks and uncertainties.
Financial Reporting: Financial statements of the acquired business and pro forma financial information are not included in this filing and will be filed by amendment within 71 days.
Investor Verification Checklist
- Verify the status of the $15 million financing transaction required to trigger the $7 million deferred payment.
- Monitor the progress of the rYP plague vaccine entering Phase II trials in Q2 2008.
- Track the status of government contract negotiations for the rPA and rYP vaccines to assess the likelihood of milestone payments.
- Review the upcoming amendment to this 8-K for the financial statements of the acquired business and pro forma information.
- Confirm the terms of the long-term manufacturing agreement with Avecia for vaccine supply.